AUSTIN, Texas -- Hepatorenal syndrome (HRS) type 1 patients showed clinically meaningful responses to terlipressin (Terlivaz) under an alternative definition of treatment success, according to a ...
– Two scientific poster presentations at EASL 2023 will detail findings of Mallinckrodt's latest research providing insight into the therapeutic effect of TERLIVAZ ® from baseline, and the clinical ...
– Pooled analysis from Phase 3 clinical trials highlights liver transplant rates in adult patients with HRS with rapid reduction in kidney function treated with TERLIVAZ1 – TERLIVAZ is the first and ...
– Findings from two clinical studies and one health economic database analysis provide insight into HRS treatment outcomes with TERLIVAZ, 1 patients' cardiac health 2 and association between hospital ...
DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...
Financing from RA Capital Management, Venrock and Vivo Capital will enable the biopharmaceutical company to advance OCE-205 for treatment of hepatorenal syndrome Phase 2 clinical trial to initiate in ...
– HRS Awareness Day will be observed annually on October 14 during National Liver Awareness Month, with the goal of raising awareness around a life-threatening condition that occurs in people with ...
Pathophysiology of hepatorenal syndrome-acute kidney injury. Cirrhosis leads to an elevation in intrahepatic vascular resistance. Splanchnic vasodilation increases the production of vasodilators ...
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of four posters in patients with hepatorenal syndrome (HRS), including a Poster of Distinction, at The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback